Post on 09-Aug-2015
d a n i - b e n n e t t . c o m
[identity] DRC logo development. 2014.
DRC
DAVA RESEARCH CONSORTIUM
DAVA RESEARCHCONSORTIUM
DRCDAVA Research Consortium
...moving community cancer research forward
DAVA ResearchConsortium
DAVA ResearchConsortium
DRC
...moving community cancer research forward
DAVA Research
Consortium
CONSORTIUMDAVA RESEARCH
...moving community cancer research forward
CONSORTIUMDAVA RESEARCH...moving cancer research forward
[identity] ACT logo development. 2013.
ACTacceleratingclinical trials ACT
accelerating clinical trials
ACTaccelerating clinical trials
ACT accelerating clinical trials
accelerating clinical trials>>ACTaccelerating clinicaltrials
AcceleratingClinical TrialsCT
ACT accelerating clinical trials
ACTaccelerating
clinical trials
ACTaccelerating clinical trials ACT
accelerating clinical trials
ACT accelerating clinical trials
ACTaccelerating clinical trials ACT
accelerating clinical trials
ACT accelerating clinical trials
ACTaccelerating clinical trials ACT
accelerating clinical trials
ACT accelerating clinical trials
ACTaccelerating clinical trials ACT
accelerating clinical trials
ACT accelerating clinical trials
ACTaccelerating clinical trials
omom
mom OMI
OmI
omeONCOLOGY MEETING EXPERTS
omiONCOLOGY MEETING INNOVATION
oncologymeeting
INNOVATION
omeONCOLOGY MEETING EXPERTS
omiONCOLOGY MEETING I N N O V A T I O N S
mONCOLOGY MEETING INNOVATION
omiONCOLOGY MEETING I N N O V A T I O N S
omeONCOLOGY MEETING EXPERTS
omeONCOLOGY MEETING
E X P E R T S
mONCOLOGY MEETING INNOVATION
omiONCOLOGY MEETING I N N O V A T I O N S
omeONCOLOGY MEETING EXPERTS
omeONCOLOGY MEETING
E X P E R T S
mONCOLOGY MEETING INNOVATION
omiONCOLOGY MEETING I N N O V A T I O N S
omeONCOLOGY MEETING EXPERTS
omeONCOLOGY MEETING
E X P E R T S
mONCOLOGY MEETING INNOVATION
[identity] OMI logo development. 2013.
[identity] Bayou Gymnastics logo. 2013.
Bayou Preschoolbuilding the future
c: 432.664.6521o: 432.614.2291f: 432.614.2281
Greg Brady402 W.1st Street | Odessa, TX 79761
SSSSSSEEE
[identity] top: ESS logo. bottom: ESS business card. 2012.
[print] graduation surprise gift card. 2014.
P R O U D
CongratulationsW E A R E S O
O F Y O U
M A Y30thO
NL
Y Redeemable
[print] dual baby shower invite. 2014.
s h ow e rBaby
Join us for a
honoring
&JohnsonAlisa
ContrerasChristina
lunchj u ly 1 4 - 1 : 0 0
[print] Halloween party invite. 2014.
Halloween party
Lunch and beverages will be provided.
Costume coNtest - The best costumes will receive prizes!Employees can wear their costumes all day
(if it doesn’t interfere with visits, conferences, etc.)or prepare just before the party
dessert coNtest - Top desserts will receive prizes!
Friday, Octob er 3 11 : 00 - 3 :00
[print] Thanksgiving potluck invite. 2014.
Thanksgiving PoTluck!
Categories: dessert & non-dessert3 winners for each categoryPLUS a best overall winner!
Contest entries must be home-made. All other food brought does not have to be home made.
Sign up excel will be circulated to share what you’ll be bringing.
Wednesday, November 26
Traditional office bake-off !
12:00 pm - 2:00 pm
[print] fundraiser invitations, recurring project 2013 and 2014.
18th annual
CASINO
night
Viva Las VegasYou are cordially invited to attend the
benefi tting St. Peter the Apostle Catholic School1201 S. Cherry LaneFort Worth, TX 76108
11/9/13 6-11 pm
To purchase tickets, please call
817-246-2032Feeling luckyYou are cordially invited to attend the
benefitting St. Peter the Apostle Catholic School
1201 S. Cherry LaneFort Worth, TX 76108
To purchase tickets, please call
817-246-2032
19th annual Viva Las Vegas
Casino nightNOV. 8 6-11 pm
[print] top: outside banner. bottom: double-sided full-window decals. 2012.
& minds
rowing godly bodiesg
w e e k d a y e d u c a t i o nouths eminoles aptistb hurchc
Train children to live the right way, and when they are old, they will not stray from it.
Proverbs 22:6
& minds
rowing godly bodiesg
ouths eminolesw e e k d a y
aptistB hurchce d u c a t i o n
proverbs 22:6
Train children to live the right way, and when they are old,
they will not stray from it.
[advertising] AML summit brochure. 2014.
3Inaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMlnoveMber 8, 2014 | Dallas, TX
Inaugural “Think Tank” on
Integrating NewMolecular Targets AMLin
5 Welcome 7 AGeNDA UNDerstANDiNG A complex DiseAse GeNomic evAlUAtioN iN Aml 8 AGeNDA epiGeNetic ApproAches for Aml immUNe ApproAches to Aml 9 AGeNDA NeW tArGets strAteGies for the fUtUre 11 BioGrAphies 33 fAcUlty 40 UpcomiNG sUmmits
agendabiographies
faculty
33
Inaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl
noveMber 8, 2014 | Dallas, TX
faculty
facultyInaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl
biographiesInaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl
SpeAkeRScamille Abboud, Md
Professor of Medicine
Washington University, St. Louis
Siteman Cancer Center
St. Louis, MO
omar Abdel-Wahab, Md
Assistant Member
Memorial Sloan-Kettering Cancer
CenterNew York, NY
Michael Andreeff, Md, Phd
Professor of Medicine and Paul
Mary Haas Chair in Genetics
Chief, Molecular Hematology &Therapy
University of Texas
MD Anderson Cancer Center
Houston, TX
daniel Arber, Md
Ronald F. Dorfman, MBBCH, FRCPATH
Professor in Hematopathology
Stanford University School of Medicine
Stanford, CA
david claxton, Md
Professor of Medicine
Penn State Hershey Cancer Institute
Hershey, PA
Robert collins, Md
Sydney and J.L. Huffines Distinguished
Chair in Cancer Research
H. Lloyd and Willye V. Skaggs Professorship
in Medical Research
University of Texas Southwestern
Medical Center
Dallas, TX
stefan Faderl, Md
Chief, Leukemia
John Theurer Cancer Center
Hackensack, NJ
james Foran, Md
Associate Professor of Oncology
Mayo Clinic
Jacksonville, FL
stefan Fröhling, Md
ProfessorHead, Molecular & Cellular Oncology
SectionGerman Cancer Research Center
National Center for Tumor Diseases
Heidelberg, Germany
Leo Luznik, Md
Associate Professor of Oncology
Johns Hopkins University
Sidney Kimmel Comprehensive
Cancer Center
Baltimore, MD
Alexander Perl, Md
Assistant Professor of Medicine
University of Pennsylvania
Abramson Cancer Center
Philadelphia, PA
jeffrey Pu, Md, Phd
Assistant Professor of Medicine
Penn State Hershey Cancer Institute
Hershey, PA
jerald Radich, Md
Associate Professor of Medicine
Fred Hutchinson Cancer Research
CenterSeattle, WA
Farhad Ravandi-Kashani, Md
Professor of Medicine
University of Texas
MD Anderson Cancer Center
Houston, TX
jorge cortes, Md
Deputy Department Chair
Chair, AML Section
D. B. Lane Cancer Research Distinguished
Professor for Leukemia Research
University of Texas
MD Anderson Cancer Center
Houston, TX
Mark Levis, Md, Phd
Director, Adult Leukemia Program
Associate Professor of Oncology
Johns Hopkins University
Sidney Kimmel Comprehensive
Cancer Center
Baltimore, MD
CHaIr
CHaIr
7
Inaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl
noveMber 8, 2014 | Dallas, TX
agendaagendaInaugural “ThInk Tank” on InTegraTIng new Molecular TargeTs In aMl
SaTurDay | NoveMber 8, 2014
7:00 aM breakfast and registration
7:45 aM Welcome and introductions
John Eckardt
Understanding a Complex Disease Jorge Cortes
8:00 aM aML landscape 2015: How are patients treated?
Charles Schiffer
8:15 aM risk adapted approach to treatment of aML
Stefan Faderl
8:30 aM outpatient management of intensive aML therapy
David Claxton
8:45 aM Prognostic impact of FLT3 mutations and treatment decisions
Richard Schlenk
9:00 aM Changes in the classification of aML
Daniel Arber
9:15 aM DISCuSSIoN
Genomic Evaluation in AML Jerald Radich
9:30 aM genomic analysis of non-responders and single cell clonal evolution
Jerald Radich
9:45 aM relevance of gPI-anchor protein in genomic stability and leukemic
transformation
Jeffrey Pu
10:00 aM breaK
Inaugural “Think Tank” on
Four Seasons Resort & Club Dallas at Las Colinas
Dallas, TX
Integrating NewMolecular Targets AMLin
8:00 am - 5:30 pmNovember 8, 2014
Summit ChairsJorge Cortes, MD
University of Texas MD Anderson Cancer Center
Houston, TX
Mark Levis, MD, PhDJohns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD
For More INForMaTIoN go To:
www.omionc.com
p r o s t a t eC A N C E R S U M M I T
Summit on Pract ica l and Emerging Trends in Prostate Cancer
1ST ANNUAL
REGISTRATION
w w w. o m i o n c . c o m
OLIVER SARTOR , MDProfessor
Tulane Univers ityNew Orleans , LA
N IC HOL AS VO G E L Z A NG , M DVice Chair SWO G GU Committee
C omprehensive Cancer C enters of NevadaL as Vegas , NV
S U M M I T C H A I R S
BALLROOMmeeting room
p r o s t a t eC A N C E R S U M M I T
Summit on Pract ica l and Emerging Trends in Prostate Cancer
1ST ANNUAL
Sunday, February 16, 2014
Genetic risk of prostate cancer: The story of common and rare variants Peter Nelson
Do chromosomal rearrangements determine poor clinical outcome in prostate cancer? (ETS, TMPRSS2-ERG) Scott Tomlins
Quantitative imaging methods for detecting metastasis and therapeutic response Glenn Liu
Predictive validity of PSA kinetics in initiation and response to chemotherapy Mitchell Gross
Prognostic biomarkers in prostate cancer Daniel Danila
Immune checkpoint blockade in prostate cancer: Clinical results and future challenges Charles Drake
Exploiting immunomodulatory antibodies in prostate cancer (new antibodies) Susan Slovin
Immunotherapy combination strategies Emmanuel Antonarakis
Cabozantinib: c-Met and VEGFR2 TKI in bone metastasis Daniel George
Sequencing and combination prospects of AR inhibitors William Figg
Therapeutic targeting of EGF family of ligands and receptors in prostate cancer William Gullick
Optimizing bone-seeking therapy in clinic Oliver Sartor
Microenvironment captives: Tasquinimod in mCRPC Walter Stadler
PARP1 inhibitors in targeted radiosensitization and resistance Karen Knudsen
Critical Determinants of Prostate CancerSusan Slovin & Walter Stadler
Immunotherapy: Implications and ChallengesPhilip Kantoff & Daniel Petrylak
New FrontiersRobert Dreicer & Daniel George
MyelomaMarch 27-28Whistler, BC Canada
MelanomaMay 3-4Dallas, TX
Pancreatic, Gastric, HCLTBD
LungDecember 13-14Dallas, TX
CLLMarch 29-30Whistler, BC Canada
Immune CheckpointsJuly 19-20Palm Beach, FL
Acute Lymphobastic LeukemiaAugust 23-24Dallas, TX
M A R M AY J U L S E P N O VA P R J U N A U G O C T D E C
Upcoming Cancer Summits for 2014
7:00 AM - 8:40 AM
9:00 AM - 10:20 AM
10:40 AM - 12:40 PM
[advertising] left: directional signage. right: large format agenda banner. 2014.
[advertising] OMI melanoma brochure. 2014.
Robert Andtbacka, MDAssistant ProfessorUniversity of Utah Huntsman Cancer InstituteSalt Lake City, UT
Nitin Chakravarti, PhDInstructorMD Anderson Cancer CenterHouston, TX
Adil Daud, MDClinical Professor Director, Melanoma Clinical ResearchUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer CenterSan Francisco, CA
Michael Davies, MD, PhDAssociate ProfessorMD Anderson Cancer CenterHouston, TX
Madeleine Duvic, MDDeputy Department ChairMD Anderson Cancer CenterHouston, TX
Rene Gonzalez, MDProfessor of MedicineUniversity of Colorado Cancer CenterDenver, CO
Kenneth Grossmann, MD, PhDAssistant ProfessorUniversity of Utah Huntsman Cancer InstituteSalt Lake City, UT
Omid Hamid, MDChief, Translational Research and Immunotherapy Director, Melanoma TherapeuticsThe Angeles Clinic and Research InstituteLos Angeles, CA
Gerald Linette, MD, PhDAssociate Professor of MedicineWashington UniversitySt. Louis, MO
Doron Lipson, PhDDirector, Computational Biology MethodsFoundation MedicineCambridge, MA
Roger Lo, MD, PhDAssociate Professor of Medicine/ DermatologyUniversity of California, Los Angeles Jonsson Comprehensive Cancer CenterLos Angeles, CA
Patricia LoRusso, DOProfessor of Hematology and Oncology Director, Experimental TherapeuticsWayne State University Karmanos Cancer InstituteDetroit, MI
David McDermott, MDAssociate ProfessorDana-Farber Cancer InstituteBoston, MA
Martin McMahon, PhDDirector of Professional Education Co-Leader, Developmental Therapeutics ProgramUniversity of California, San Francisco Helen Diller Family Comprehensive Cancer CenterSan Francisco, CA
James Mier, MDAssociate ProfessorDana-Farber Cancer InstituteBoston, MA
Steven O’Day, MDDirector of Clinical Research Director of Los Angeles Skin Cancer InstituteBeverly Hills Cancer CenterBeverly Hills, CA
Elise Olsen, MDProfessor of Dermatology Professor of MedicineDuke UniversityDurham, NC
Sapna Patel, MDAssistant ProfessorMD Anderson Cancer CenterHouston, TX
Lauren Pinter-Brown, MDClinical Professor Director, UCLA Lymphoma ProgramUniversity of California, Los Angeles Jonsson Comprehensive Cancer CenterLos Angeles, CA
Douglas Reintgen, MDProfessor, College Of Medicine SurgeryUniversity of Southern Florida Lakeland Regional Cancer CenterTampa, FL
Alain Rook, MDDirector, Photopheresis Program Professor of DermatologyUniversity of Pennsylvania Abramson Cancer CenterPhiladelphia, PA
Merrick Ross, MDProfessor, Department of Surgical OncologyMD Anderson Cancer CenterHouston, TX
William Sharfman, MDAssociate Professor of Oncology and DermatologyJohns Hopkins University Sidney Kimmel Comprehensive Cancer CenterLutherville, MD
Jeffrey Sosman, MDProfessor of Medicine Director, Melanoma & Tumor Immunotherapy ProgramVanderbilt University Ingram Cancer CenterNashville, TN
Clifford Tepper, PhDAssociate Research BiochemistUniversity of California, DavisSacramento, CA
Jennifer Wargo, MDAssistant ProfessorMD Anderson Cancer CenterHouston, TX
Ian Watson, PhDPostdoctoral FellowMD Anderson Cancer CenterHouston, TX
Jeffrey Weber, MD, PhDSenior MemberMoffitt Cancer CenterTampa, FL
Martin Weinstock, MDProfessor of DermatologyBrown UniversityProvidence, RI
Michael Wong, MD, PhDProfessor of MedicineUniversity of Southern California Norris Comprehensive Cancer CenterLos Angeles, CA
FacULTY
Michael Atkins, MDGeorgetown University
Lombardi Comprehensive Cancer CenterWashington, DC
Patrick Hwu, MDMD Anderson Cancer Center
Houston, TX
CONfERENCE CHAIRMEN
T-cell MalignanciesMelanoma cutaneous&
accoMMoDaTIoNS
The Four Seasons Resort and Club Dallas
at Las Colinas is located in the hills of Irving,
Texas just minutes away from Downtown
Dallas and convenient to the Dallas/Fort
Worth International Airport (DFW) and Dallas
Love Field Airport (DAL). Exceptional service
in a retreat environment, an excellent location
for pleasure and business travel.
A small block of Superior rooms has been
set aside at a special rate of $185.00 plus
applicable taxes. In order to receive this
special rate, please call (972) 717-0700 and
identify yourself as part of the Summit on
Melanoma & Cutaneous T-cell Malignancies.
Room type and the special room rate is
subject to availability at the time of the
reservation. Note the room block will close on
April 11, 2014.
For questions, please email
Gregory Pynes at
gpynes@davaonc.com.
TraVEL INForMaTIoN
The Four Seasons Resort and Club Dallas at
Las Colinas is conveniently located next to
Dallas/Fort Worth International Airport (DFW)
and Dallas Love Field Airport (DAL).
Registration fees include continental breakfast, working lunches, refreshment breaks and
syllabus materials.
First Name _____________________ Middle Initial ____ Last Name ___________________
Credentials: _______ c Physician c Fellow c PA-C c PhD c Pharmacist
Mailing Address _____________________________________________________________
Suite______ City __________________________ State _____ Postal/Zip Code __________
Phone Number_______________________________Fax ___________________________
E-mail ____________________________________________________________________
(your confirmation will be sent via e-mail.)
c Check here if you have any special dietary needs; please specify below:
___________________________________________________________________________
Please complete the registration form and mail it with your payment to the address below, or
visit www.regonline.com/heme to register online. Checks and credit cards are accepted. To
register by phone or fax, please call (214) 593-0504 or fax (214) 889-7070 (credit cards only).
Please make checks payable to Dava Oncology, LP.
Method of Payment
c Check c VISA c MasterCard c Discover c American Express
Name as it appears on credit card _______________________________________________
Signature __________________________________________________________________
Card Number _______________________________________________________________
Security Code ____________________________ Expiration Date _____________________
(On the back of most credit cards, front if American Express)
Billing Address (if different from above; zip code required):
Address ___________________________________________________________________
Suite______ City __________________________ State _____ Postal/Zip Code __________
Dava Oncology, LP fully complies with the legal requirements of the ADA and the rules and
regulations thereof. If any participant in this activity is in need of accommodations, please
notify us in order to receive service. Please call (214) 593-0504.
Please mail payments or inquires to:
Dava Oncology, LP
12400 Coit Road
Suite #980
Dallas, TX 75251
ThrEE WaYS To rEGISTEr
1.) Go to our web site:
www.regonline.com/heme
2.) Call or fax our office (credit card only)
p: (214) 593-0504
f: (214) 889-7070
3.) Complete the registration form and mail it
with your payment to the address below
(Checks and credit cards are accepted).
Dava Oncology, LP.
12400 Coit Road Suite #980
Dallas, TX 75251
Choose one of the following options:
Registration Option
c Live and On-Demand Access c Virtual Meeting and On-Demand Access
$325.00
$295.00
T-cell MalignanciesMelanoma cutaneous&
MK-3475 experience in melanoma
Omid Hamid
Inhibition of PD-L1 in melanoma
Patrick Hwu
Immunologic effects of BRAF inhibitor therapy
Jennifer Wargo
Sequence therapy with immune checkpoint and MAPK inhibitors
David McDermott
Novel combinations with immune checkpoint inhibitors
Jeffrey Weber
Role of HD IL-2 in the immune checkpoint era
Michael Wong
Debate: Should patients with BRAFmut metastatic melanoma
get a BRAF+/- MEK inhibitor first-line?
Breakout session
3:00 PM - 4:30 PM
Challenging cases for discussion
John Eckardt
Brain metastasis in melanoma therapy in the era of new immune
and targeted therapies
Clifford Tepper
Other skin Malignancies
7:00 AM - 8:45 AM
CTCL: Biology and current classification
Martin Weinstock
Treatment of early stage CTCL
Elise Olsen
Systemic therapy for CTCL
Alain Rook
Targeted therapy in clinical trials for CTCL
Madeleine Duvic
New therapies in development for CTCL at UCLA
Lauren Pinter-Brown
new targets in Melanoma
9:00 AM - 12:00 PM
Comprehensive genomic characterization of cutaneous
melanoma Ian Watson
Novel combination clinical trials for nivolumab in melanoma
TBD
NRAS and CDK targeted therapy in melanoma
Michael Davies
Current experience with c-KIT mutated melanoma
Adil Daud
Targeting ERK: PD-0325901
Patricia LoRusso
Biomarker analysis predicts antitumor activity of ipilimumab
Nitin Chakravarti
Immune related melanoma gene expression profile predicts for
neoadjuvant ipilimumab clinical benefit
Ahmad Tarhini
BISH RNAiSTMN1 nanoplex early assessment in melanoma
John Nemunaitis
Genomic and Prognostic evaluation of Melanoma
5:00 PM - 6:30 PM
The role of class 1 PI3’-kinases in the progression and
maintenance of BRAF mutated melanoma
Martin McMahon
Melanoma next generation sequencing: Biological and clinical
significance
Doron Lipson
Targeting p53 through HDM2 inhibition in melanoma
James Mier
Genetic and adaptive resistance to BRAF and MEK inhibitors
Roger Lo
Gene expression profiling as a predictor for early stage disease
Merrick Ross
advances in early stage Disease
6:45 PM - 8:00 PM
Melanoma nodal staging: The significance of non-sentinel lymph
node metastases
Douglas Reintgen
Surgical approach to locally advanced and advanced
melanoma Merrick Ross
advances in the standard of care for Melanoma
7:00 AM - 10:15 AM
Who can we cure with adjuvant therapy in melanoma?
Kenneth Grossmann
Where we were then and where we are now?
Michael Atkins
Immunotherapy: From IL-2 to TIL’s to CAR-T therapy
Patrick Hwu
Vemurafenib: promise and pitfalls
Steven O’Day
Best of both worlds: Increased activity & decreased toxicity of
BRAF/MEK combinations
Rene Gonzalez
Oncolytic immunotherapy: Unlocking its potential
TBD
Clinical activity of oncolytic immunotherapy in melanoma
Robert Andtbacka
Identifying the right patient for oncolytic immunotherapy
Howard Kaufman
targeting immune checkpoint inhibitors in Melanoma
10:30 AM- 3:00 PM
CTLA-4: A breakthrough in melanoma treatment
Gerald Linette
Getting the most out of ipilimumab combination
Sapna Patel
Toxicity management of immune checkpoint inhibitors
William Sharfman
Nivolumab single-agent and combination experience in
melanoma Jeffrey Sosman
FrIDaY | May 2
SaTUrDaY | May 3
SUNDaY | May 4
For more information or registrat ion, please v is itwww.regonl ine.com/heme
May 2nd-4th, 2014
F O U R SE AS ON S R E S ORT A N D C LU B
DA L L AS AT L AS C OL I NAS , T X
M ic ha e l at k i n s , M DDeputy Direc tor & Professor
Georgetown Univers ityLombardi C omprehensive Cancer C enter
Washington, D C
Pat r ic k h w u, M DDepar tment Chair
MD Anderson Cancer C enterHouston, T X
S U M M I T c h a I r S
1ST ANNUAL SUMMIT ON PRACTICAL AND EMERGING TRENDS IN
T-cell MalignanciesMelanoma cutaneous&
[advertising] large format retractable banner. 2014.
2014SUMMIT CALENDAR
MAR
FEB
MAY
JUL
AUG
SEP
DEC
ProstateFebruary 15-16 | Dallas, TX
Oliver Sartor, MDNicholas Vogelzang, MD
MyelomaMarch 27-28 | Whistler, BC Canada
Leif Bergsagel, MDSagar Lonial, MD
Sundar Jagannath, MD
MelanomaMay 3-4 | Dallas, TX
Michael Atkins, MDPatrick Hwu, MD
Harnessing the Immune SystemJuly 19-20 | Palm Beach, FL
Michael Atkins, MDDrew Pardoll, MD, PhD
Mario Sznol, MDSteve Rosenberg, MD, PhD
GI MalignanciesSeptember 27-28 | Dallas, TX
David Ilson, MD, PhDAlex Grothey, MD
LungDecember 13-14 | Dallas, TX
Paul Bunn, MDRoy Herbst, MD, PhDRavi Salgia, MD, PhD
Acute Lymphoblastic LeukemiaOctober 18-19 | Houston, TX
Jorge Cortes, MDCarl June, MD
Ching-Hon Pui, MD
Chronic LymphocyticLeukemiaMarch 29-30 | Whistler, BC Canada
John Byrd, MDRichard Furman, MD
Wyndham Wilson, MD, PhD
o m i o n c . c o m
[advertising] oncology meeting poster designs and syllabus layout. bottom: table tents. 2013.
MAPPLE EMERALD HOTELNEW DELHI
SEPTEMBER 16, 2013
KALA AZARALLEVIATION INITIATIVE
2ND ANNUAL
SEPTEMBER 20, 2013
INDIA MATERNAL HEALTH INIT IAT IVE MEET ING
MAPPLE EMERALD HOTELNEW DELHI
SEPTEMBER 20, 2013
2ND ANNUAL
Jawaharlal Nehru Medical College, Aligarh Muslim University
Imam BanoAligarh
India Maternal Health Initiative
Jawaharlal Nehru Medical College, Aligarh Muslim University
Imam Bano Aligarh
India Maternal Health Initiative
AGENDA
5:00 PM Discussion and Q&A5:30 PM ADJOURN7:00 PM Dinner and Social Event
SUNDAY, SEPTEMBER 15, 2013INDIAPOD AND DATA ANALYSIS8:30 AM Capabilities of the IndiaPOD and its use in Prospective Data Management and Analysis
Taizoon Khokhar and Dr. Vinay Jain8:45 PM Discussion and Q&A
RECENTLY ACTIVATED IPOI GRANT SITES Meeting Moderators: Dr. Vinay Jain9:00 AM Kamla Nehru Medical College, Allahabad
Dr. Sonia Tiwari 9:12 AM Nizam’s Institute of Medical Sciences
Dr. Vijay Gandhi Linga 9:24 AM Institute of Hematology, Medical College Kolkata
Dr. Kishore Kumar 9:36 AM Indira Gandhi Institute of Medical Sciences, Shimla
Dr. Ashwini Sood9:48 AM Nil Ratan Sarkar Medical College Hospital, Kolkata
Dr. Manik Mondal10:00 AM Indira Gandhi Institute of Medical Sciences, Patna
Dr. Rajesh Singh10:12 AM Thanjavur Cancer Hospital
Dr. Arun Seshachalam10:24 AM SSKM Institute of Post Graduate Medical Education & Research, Kolkata
Dr. Prafulla K. Mishra10:36 AM Government Medical College, Nagpur
Dr. Krishna Kamble10:48 AM Government Medical College, Jammu
Dr. Sanjeev Digra11:00 AM Tea Break11:30 AM The Role of the Private Practitioner in Improving Pediatric Oncology Outcomes
Dr. Ramandeep Arora, Max Superspecialty Hospital
INDIA PEDIATRIC ONCOLOGY MEETING
INDIA PEDIATRIC ONCOLOGY INITIATIVE MEETING
5TH ANNUAL
The purpose of the 2013 INDIA PEDIATRIC ONCOLOGY INITIATIVE (IPOI) Meet ing, in keeping with the mission of J iv Daya Foundat ion, is to enhance the infrastructure and del ivery of pediatr ic oncology care in India. The meet ing is designed as a forum where current strategies wi l l be reviewed and new ideas for J iv Daya Foundat ion to become involved in pediatr ic oncology efforts wi l l be discussed. Current grant recipients wi l l a lso report on the measurable impact that has been made through the IPOI partnership.
Outcomes of this meet ing should include the fol lowing:
• Tost imulatediscussionamongstcol leaguesto learnfromoneanotherandaddresscommonissues which are prevalent in pediatr ic oncology
• Toreviewtheut i l izat ionofgrantdol larsandassessthe impactmade,andtodiscusshowimpactwi l l be made in the future
• Todiscussopportuni t ies for increasingaccessibi l i ty topathological test ing
• To learnabout theavai labi l i tyof f inancial resourcesforpediatr iccancerpat ientsandconnect local donor agencies with inst i tut ions and pat ients in need
• To ident i fywaysofharnessingtechnologyto improveoutcomes
• Tounderstandthenextstepsforanalysisof dataanddiscussthepotent ial ut i l izat ionofprospect ive data in securing future grants or publ icat ion of research
• To ident i fyareasofneedandnewprojects for IPOIsupport
Mapple Emerald HotelNew Delhi, India
SEPTEMBER 14-15, 2013
[advertising] oncology clinic adboard materials. 2013.
Terrace RoomLobby Level
PI3K INHIBITORS IN NHL ADVISORY
BOARD
FRIDAY, NOVEMBER 1, 2013The Roosevelt Hotel
New York
meeting room:
Mark LevonyakPresident
PI3K INHIBITORS IN NHL ADVISORY
BOARD
[advertising] OMI multiple myeloma brochure. 2013.
U P C O M I N G C O N F E R E N C E S :
O N C O L O G Y M E E T I N G I N N O VAT I O N SA D I V I S I O N O F D AVA O N C O L O G Y
1 2 2 2 M E R I T D R . | D A L L A S , T X( 2 1 4 ) 3 6 0 - 7 4 7 3
CONFERENCE CONFERENCE
Immune CheckpointsSymposium on Immune Checkpoints
AUG 2-4 | DALLAS, TXConference Chairman: Sanjiv S. Agarwala, MD
Multiple MyelomaSymposium of Multiple Myeloma
SEP 6-8 | DALLAS, TXConference Chairman: J. Tate Thigpen, MD
Lung CancerLung Cancer Congress
NOV 1-3 | DALLAS, TXConference Chairman: ROY HERBST, MD, PHD
MelanomaSymposium on Melanoma and Other Cutaneous Malignancies
OCT 4-6 | DALLAS, TXConference Chairman: Oliver Sartor, MDDavid McLeod, MD
Prostate CancerProstate Cancer Congress
TBD | DALLAS, TXConference Chairman: Joyce O’Shaughnessy, MD
• Molecularlungcancerla
ndscapefor2013
• Newandemergingmolecu
lartargets
• Challengesinpersonaliz
inglungcancertherapy:tis
sueacquisition
• ManagingresistancetoE
GFRandALKTKIs
• Emergingtargetedagents
forNSCLCandSCLC
• Clinicaltrialdesignsfort
hemolecularera
• Newdiagnosticplatforms
forpersonalizedmedicine
• Newclinicaltrials
I N S I G H T S A N D O B J E C T I V E S :
technologyI N T E G R A T I O N
LIVE streamingandVIRTUAL meetingwithondemand
convenienceviewing
Keyword search optimization
l inkingtextandcommentsearchr
esultstothecorrespondi
ngvideo
andtranscripttext,toexp
editeindependentresear
chandmanagement
reporting
E-syllabus and web slide sharing
withoptimale-notessynchronizedt
othevirtualmeeting
Audience polling and surveys
providinginsightstoassi
stwithclinicalandcommercialdecisi
ons
multiple myeloma
G L O B A L T U M O R S U M M I T
C O N F E R E N C E C H A I R M A N
I N V I T E D F A C U L T Y
Bart Barlogie, MD, PhDposition
Brian Durie, MDposition
Rafael Fonseca, MDposition
Joseph Mikhael, MDposition
Nikhil Munshi, MDposition
Ruben Niesvizky, MDposition
Noopur Raje, MDposition
S. Vincent Rajkumar, MDposition
Paul Richardson, MDposition
David Vesole, MD, PhDposition
Ravi Vij, MDposition
Michael Wang, MDposition
Jeffrey Zonder, MDposition
Jesus San Miguel-Ayanz, EUposition
Michael Attal, EUposition
Antonio Palumbo, EUposition
Maria Mateos, EUposition
Pleter Sonneveld, EUposition
xxposition
1
2
3
4
A
B
C
ADCC Antibody Dependent Cell-mediated Cytotoxicity (ADCC): • Recognition of the Fc region of a
Mab by NK cells through the Fc-receptor (A) activates release of perforin and granzymes (B) that lyse the tumor cell (C)
CDC Complement Dependent Cytotoxicity (CDC): • Binding of the C1q complement
factor to the Fc region of a Mab (1), activates the proteolytic cascade of the complement classical pathway (2) to form a membrane-attackcomplex (3) resulting in lysis oftumor cells (4)
Direct Direct Cytotoxicity:• Recently described non-apoptotic
cell death activates a lysosomal-dependent pathway involving intracellular release of cathepsinproteases and subsequent membrane permeabilization (Alduaij et al., Blood. 2011; 117; p4529)
ADCC
CDC
Direct
multiple myelomaG L O B A L T U M O R S U M M I T
SEPTEMBER 6, 7, 8OMNI MANDALAY
DALLAS, TX
Oncology Meeting Innovations
technologyT H R O U G H
knowledgeA D V A N C I N G
[advertising] OMI lung cancer summit brochure. top, right: email campaign. 2013.
technologyI N T E G R A T I O N
INSIGHTS AND OBJECTIVES:- Molecular lung cancer landscape for 2013
- New and emerging molecular targets- Challenges in personalizing lung cancer therapy: tissue acquisition
- Managing resistance to EGFR and ALK TKIs- Emerging targeted agents for NSCLC and SCLC
- Clinical trial designs for the molecular era- New diagnostic platforms for personalized medicine
- New clinical trials
For Investigators and Research Staff December 14-15, 2013
Omni MandalayDallas, TX
Dear Investigator, You are cordially invited to attend the OMI Lung Cancer Global Tumor Summit . We encourage you to take advantage of this invitation by indicating your participation below, please note there are two options: _____ Yes, I am able to attend on this summit. _____ No, I am unable to attend. However, please extend the invitation to my colleague: (Name, email)_________________________________________________
You may reply by fax to 214-889-7070. For any questions, please call Gregory Pynes at 214-451-4519.
Sincerely,
OMI Staff division of DAVA Oncology
www.omi.com
INVITED FACULTYAlex Adjei, MD, PhD
Roswell Park Cancer Institute
Julie Brahmer, MD
Johns Hopkins
Ross Camidge, MD
University of Colorado Denver
David Gandara, MD
UC Davis Comprehensive Cancer Center
Barbara Gitlitz, MD
USC/Norris Comprehensive Cancer Center
Gavin Gordon, PhD
Brigham and Women’s Hospital
Ramaswamy Govindan, MD, PhD
Washington University School of Medicine
Raffit Hassan, MD
National Cancer Institute
John Heymach, MD, PhD
MD Anderson Cancer Center
Anthony John Iafrate, MD, PhD
Massachusetts General Hospital
Edward Kim, MD
Carolinas HealthCare System
Kartik Konduri, MD
Texas Oncology
Corey Langer, MD
University of Pennsylvania School of Medicine
Patrick Ma, MD, MSc
Case Comprehensive Cancer Center
Tony Mok, MD
Prince of Wales Hospital, Shatin, HKSAR, China
Sai-Hong Ignatius Ou, MD, PhD
UC Irvine
William Pao, MD, PhD
Vanderbilt-Ingram Cancer Center
Suresh Ramalingam, MD
Emory School of Medicine
Rafael Rosell, MD, PhD
Germans Trias & Pujol Hospital, Barcelona, Spain
Charles Rudin, MD, PhD
Johns Hopkins
Alan Sandler, MD
OHSU
Joan Schiller, MD
UT Southwestern Medical Center
Lecia Sequist, MD, MPH
Massachusetts General Hospital
Geoffrey Shapiro, MD, PhD
Dana Farber Cancer Institute
Alice Shaw, MD
Massachusetts General Hospital
George Simon, MD
MD Anderson Cancer Center
Mark Socinski, MD
University of Pittsburgh
Jean-Charles Soria, MD, PhD
Institut Gustave Roussy, Villejuif, France
David Spigel, MD
Tennessee Oncology/SCRI
Masahiro Tsuboi, MD, PhD
Yokohama City University Medical Center, Yokohama, Japan
Everett Vokes, MD
University of Chicago
Heather Wakelee, MD
Stanford University
Howard (Jack) West, MD
Swedish Cancer Institute
INVITED FACULTY
SESSION 1
BIOLOGY OF LUNG CANCER
TIME Sorting through Tumor Heterogeneity in
Lung Cancer
TIME Mutations and Translocations in Lung
Cancer: What do the Details Teach Us?
TIME TheInflamedTumorPhenotypeasa
PredictorofResponse
SESSION 2
TARGET-SPECIFICTREATME
NTOFLUNGCANCER
EGFR: Continuing Lessons
TIME Erlotinib – What Have We Learned
Since 2004?
TIME MechanismsofResistancetoEGFR
TKIs
TIME ApproachestoOvercomingtheT790M
Resistance Mutation
TIME TheNextGenerationsofEG
FR-
Targeted Agents
TIME Fully Human EGFR Antibodies in
Squamous NSCLC
TIME IsthereaRoleforEGFRInh
ibitionin
the Adjuvant Setting?
EML4-ALK: Discovering the Optimal Therapeutic
ApproachTIME ALKinPerspe
ctive:Identification
and Biology
TIME Crizotinib: Lessons Learned Since
Approval
TIME Next-Generation ALK Inhibitors
New Frontiers in Angiogenesis
TIME Bevacizumab–HowdoWeOptimize
theRoleofVEGFInhibition?
TIME TargetingtheVEGFR-2Extr
acellular
Domain
TIME TargetingtheDLL4/Notchp
athway
TIME InhibitorsoftheAng/Tieax
is
Integrating Immune Checkpoint Inhibitors in Lung
Cancer Therapy
TIME OverviewofImmuneCheckpoi
nts
TIME ImmuneCheckpointInhibitorsin
Development
TIME PracticalIssuesfortheApp
lication
AGENDA ofImmuneCheckpoi
ntInhibitorsin
LungCancer:OpenDiscus
sion
Combinations with MET Inhibitors
TIME BiologyofMET:WhatHaveWe
FoundinthePast12Months
?
TIME ThePathologist’sPerspecti
ve:What
ShouldWeBeMeasuringforMET
Inhibitors?
TIME METInhibitorsinDevelopm
ent:
Antibodies
Targeting the KRAS Pathway
TIME BiologyofKRASandBRAF
Mutations
TIME InhibitorsoftheKRASPath
wayand
AgentsforKRAS-mutantNSCLC
SESSION 3
CONTINUINGTHEOPTIMIZA
TIONOF
CHEMOTHERAPY
TIME WhatistheOptimalCytotoxicA
pproach
forSquamousNSCLC?
TIME CustomizedChemotherapy:Findingthe
Holy Grail
TIME Combinations with Cytotoxic Agents in
theAgeofTargetedTherapy
BREAKOUT SESSION 1
CASE-BASEDPATHWAYDEVELOPM
ENT
TIME GuidelinesforValue-based
CancerCare
TIME What Molecular Tests Should I Be
Ordering?
TIME WhatistheRoleofHistologyi
ntheAge
ofMolecularMarkers?
TIME Case-basedPanelDiscussi
on
BREAKOUT SESSION 2
EMERGINGAGENTS&PAT
HWAYS
TIME Chromosomal Translocations
TIME Beyond EGFR: New Growth Factor
ReceptorTargets
TIME HSP90Inhibitors
TIME CurrentStateofPI3KPathw
ay-
targeted Agents
TIME Antibody-drug Conjugates
SUMMIT IN
DECEMBER 14-15, 2013OMNI MANDAL AY
DALL AS, TX
CONFERENCE CHAIRMEN: ROY HERBST, MD, PHDYale UniversityPASI JANE, MD, PHDDana Farber Cancer Institute
PRACTICAL AND EMERGING AGENTS ININ LUNG CANCER
2013 SUMMIT ONPRACTICAL AND EMERGING AGENTS
IN LUNG CANCER
DECEMBER 14-15, 2013RITZ-C ARLTON | DALL AS, TX
ROY HERBST, MD, PHDYale UniversityNew Haven, CT
PASI JANNE, MD, PHDDana Farber Cancer Institute
Boston, MA
• Biology of Lung Cancer• Target-specific Treatment of Lung Cancer - EGFR: Continuing Lessons - EML4-ALK: Discovering Optimal Therapeutic Approach - New Frontiers in Angiogenesis - Integrating Immune Checkpoint Inhibitors in Lung Cancer Therapy - Combinations with MET Inhibitors - Targeting the KRAS Pathway• Continuing the Optimization of Chemotherapy• Case-based Pathway Development• Emerging Agents and Pathways
OMI’s Oncology Translational and Global Tumor Summits are designed to convene 80+ faculty and research consortia members, from some of the top academic and community centers across the nation, and our industry partners. These robust, 3-day summit programs are developed in collaboration with our medical staff and our world-renowned expert chairs. The faculty and scientific presenters are selected based on their ongoing research and peer-reviewed publications. The overall goal being to better understand new treatment options available within each therapeutic area, facilitate dynamic discussion and foster professional relationships.
OVERVIEW
AGENDA
20
NEXTPREV►◄ONE
Oncology SM
Your ONE source for cancer knowledge
1ST ANNUAL EXPERT FORUM ON ANGIOGENESIS | APRIL 26-27, 2013 • SCOTTSDALE, AZ
| DONALD MCDONALD, MD, PhDTargeting Resistance to Antiangiogenic Therapy
Dr. McDonald presented the first lecture on overcoming resistance to antiangiogenic agents.
The first part of his presentation addressed the question of what limits the activity of VEGF inhibitors in cancer therapy. VEGF inhibitors prune tumor blood vessels and slow tumor growth, which results in tissue hypoxia and changes in gene expression. One of the genes that may be upregulated is MET, which induces invasion and metastasis. Therefore, instead of turning a large tumor into a smaller, less malignant tumor, the result of VEGF pathway inhibition may be a smaller but more invasive tumor. Other mechanisms of resistance include revascularization and enhanced metastasis (Figure 1).1
To address this challenge, Dr. McDonald introduced two ways of simultaneously targeting the vasculature and the tumor (Table 1). The first approach is to block both VEGF and MET signaling. An example of this approach is cabozantinib, a TKI with activity against VEGFR-2 and MET, which was investigated in patients with castrate-resistant prostate cancer (CRPC). In a randomized phase II trial, bone scan improvement occurred in 68% of patients, 67% of patients experienced a corresponding reduction in pain, and 56% of patients experienced a decrease or discontinuation of pain medication.2 Two phase III trials are further investigating cabozantinib in CRPC. Although these results are encouraging, it is important to point out that the exact molecular targets in this setting have not yet been determined. The second approach is the addition of an oncolytic virus, such as JX-594, which in HCC has been shown to infect both tumor cells and tumor endothelial cells and therefore act in a complementary fashion to VEGF inhibitors.3
Dr. Bertolini asked if targeting pericytes might also be explored. Dr. McDonald said that question is being explored, but he believes resistance will eventually develop. Dr. Kerbel said that data from Dr. Napoleone Ferrara suggested that targeting pericytes disrupts the lung vasculature, which leads to increasing susceptibility to tumor cell infiltration.
• Blocking VEGF signaling initially inhibits tumors, but the resulting hypoxia changes tumor biology to a more invasive phenotype, which leads to resistance to therapy• Simultaneous targeting of VEGF and MET signaling might prevent tumor invasiveness• Targeting both tumor cells and tumor endothelial cells with an oncolytic virus might complement VEGF pathway inhibition
Q/A
Table 1. Potential Approaches to Evade Resistance to Antiangiogenic AgentsApproach ExampleCombined blockade of VEGF and MET signaling Cabozantinib
Infection of vascular and tumor cells by oncolytic virus JX-594
References:1. Pàez-Ribes et al., Cancer Cell. 2009; 15: p2202. Smith et al., J Clin Oncol. 2013; 31: p4123. Kirn and Thorne, Nat Rev Cancer. 2009; 9: p64
Figure 1. Overview of Mechanisms to Escape Antiangiogenic Therapy
42
NEXTPREV►◄
ONEOncologySM
Your ONE source for cancer knowledge
1ST ANNUAL EXPERT FORUM ON ANGIOGENESIS | APRIL 26-27, 2013 • SCOTTSDALE, AZ
Preclinical and Biology
Figure 1. Tumor Blood Vessel Heterogeneity and Differential Sensitivity to VEGF Inhibition
What is the True Importance of Angiogenesis in Cancer?
Harold Dvorak, MD>>• Humantumor
bloodvesselsareheterogen
eous(Figure1)
• Sometumorscanco-optexi
stingbloodvesselsanddono
trelyonangiogenesis
• Latevesselsinadvancedtum
orsmayloseVEGFdepende
ncy,sotargetingVEGFmayb
emoreeffectiveinearlier
tumors
• Otherangiogenicfactorssho
uldbetargeted,aswell
Q/A Dr. Hecht mentioned that the TML/VELOUR trials in CRC have
patients who have received antiangiogenic agents for a prolonged period of
time. The scans from these patients might be examined to investigate the
differences in progression patterns in the primary tumor versus metastases.
ONEOncologySM
Your ONE source for cancer knowledge
2
1ST ANNUAL EXPERT FORUM ON ANGIOGENESIS | APRIL 26-27, 2013 • SCOTTSDALE, AZ
NEXTPREV►◄
TABLE OF CONTENTS
Clicking on the ONE logo throughout the document
will bring you back to the Table of Contents.
3 INTRODUCTIONS
4 ABOUT DAVA
5 HIGHLIGHTS
6 VEGF SIGNALING
HOW DO WE OPTIMIZE THE USE OF ANTIANGIOGENIC TKIs?
12 Are Antiangiogenic TKIs Being Dosed Correctly? Eric Jonasch, MD
13 WhyDon’tAntiangiogenicT
KIsEnhancetheEfficacyo
fChemotherapy?Robert Kerbel, MD
14 ChemotherapyInducesMobilizat
ionofEndothelialProgenit
orCells(EPCs)
19 ShouldMetronomicChemotherapyBeU
sedWhenCombiningwith
Antiangiogenic TKIs? Francesco Bertolini, MD, PhD
OVERCOMING RESISTANCE TO ANGIOGENIC THERAPY
20 TargetingResistancetoAn
tiangiogenicTherapy
Donald McDonald, MD, PhD
21 ClinicalExperiencewithA
cquiredResistancetoAntia
ngiogenicAgents Roberto Pili, MD
22 ALK-1/Endoglin Signaling
NEXT-GENERATION TARGETS AND AGENTS
25 TargetingCD105(Endoglin
) Michael Gordon, MD
26 InhibitingActivinReceptor
-LikeKinase1(ALK-1)
Rupal Bhatt, MD, PhD, MMS
27 IntegrinInhibitors Andrew Mazar, PhD
DLL4/NOTCH SIGNALING
31 InhibitorsofDLL4/Notch
Adrian Harris, MD, DPHIL
32 Angiopoietin/TieSignaling
36 TargetingtheAngiopoietin
Pathway Hellmut Augustin, DVM, PhD
PREDICTING RESPONSE TO ANTIANGIOGENIC THERAPY
37 CandidatePredictiveBiom
arkers Murray Robinson, PhD
38 UsingImagingasaPredictiveMark
er Ronald Kord, MD, PhD
39 ImpactofOff-TargetEffectso
nAntiangiogenicAgents:T
oxicity
andEfficacy Howard West, MD
PREDICTING RESPONSE TO ANTIANGIOGENIC THERAPY
40 IsThereaRoleforAngioge
nesisInhibitionintheAdjuv
antSetting? Lee Ellis, MD, Randolph Hecht, MD
41 ChoosingtheOptimalAntiangiog
enicStrategyafterProgres
sion Randolph Hecht, MD
BIOLOGY AND PRECLINICAL DATA
42 WhatistheTrueImportanceofA
ngiogenesisinCancer?
Harold Dvorak, MD
43 ImpactofAntiangiogenicAge
ntsonHIFandCancerStem
Cells Giovanni Melillo, MD
43 ImprovingPreclinicalModels
forAntiangiogenicAgents
Robert Kerbel, PhD
44 MolecularMarkersofTumorEndotheliu
m Brad St. Croix, PhD
45 Angiocrine Signaling Lee Ellis, MD
46 BIOGRAPHIES
[advertising] executive summary booklet. 2013.
[advertising] new gym advertising. 2013.
PRODUCING TOP ELITE LIFTERSTrain with us:
Monday, Wednesday, FridaySunday
6:00 pm10:00 am
We support all federations.
info@badattitudegym.com
Raw, single-ply, multi-ply...
All are welcome!
[advertising] rotating web banner campaign samples. 2012.
[advertising] Louisiana Tech powerlifting flyer. 2012.
[advertising] online course postcard. 2014
Secure registration-based access to summit curriculumQuiz-based curriculum designed to support the comprehension and
reinforcement of Summit highlights
15-20 hrsRecorded and Transcribed Summit content
6 MODULEswith Q&A
www.omiu.udemy.com
Incorporation of presentation slides, images, and videos
ONLINE OPENcurriculum
F R E E
Online course development through integration with an industry-leading massive open online course platform
[advertising] Unicef call-to-action poster. 2013.
It’s not his job...
It’s YOURS
against child laborSPEAK UP
www.unicef.org
[advertising] Unicef call-to-action poster. 2012.
LIGHTEN his load.SPEAK UP.
This is the weight of
SILENCE
www.unicef.org
[advertising] case study: magazine ad. 2012. Magazine Ad
[advertising] medical illustration examples.
Neck (cervical)lymph nodes
Node
Liver
Spleen
Groin (inguinal)lymph nodes
Armpit (axillary)lymph nodes
Lymphatic vessels
Bone marrow
Diaphragm
Thymus
Extracellular matrixImmune cells
Pancreatic cancer cells
Desmoplasticstroma
Hedgehog signal
Cancer cell Cancer-associatedfibroblastsproliferate
Blood vessel formation is limited;poor drug delivery
[advertising] medical illustration examples.
Lipoic acid
PDH Complex
NADH
NADHElectrons carried by NADH
Stage 1: GlycolosysGlucose Pyruvic acid
ATP ATP
Stage 2: Krebs cycle Stage 3:
Electron transport/chain/ATP synthase
action
Cytoplasm
Mitochondrion
CO2
CO2
Survival Proliferation
ATPATP
Incoming lymph vessel
Germinal center
Follicle
Medulla
Vein
Artery
Paracortex
Cortex
Outgoing lymph vessel
[advertising] medical illustration examples.
KDM TET
Nucleus
Cytoplasm
Altered epigenetic regulation
Altered differentiation and tumorigenesis
CH3 CH3
K G CA T
2-HGα-KG
IDH1/2mutant
4
Apoptosis(cell death)
1ADC in plasma
3ADC receptor complex is internalized
2 ADC binds to tumor-associated antigen to receptor
Cytoxic agent
Cancer cell
Dead cancer cell
[digital] ONE video platform. 2013.
TUMOR COMPASS
Lung Cancer
xxx
DOWNLOAD VIDEO AUDIO
Ribus mos re voluptis porehentias doloremposam ut pa ped quatibusda verspidia qui ullabo. Tate nim nonsece atistium lab ipsamen ditate porem arum rem remperro volorectota verias ad ulluptatem simoluptum quae recaece pudam, sin rem nis quam voluptas simet ut quam,
TUMOR COMPASS
Lung Cancer
xxx
DOWNLOAD VIDEO AUDIO
Ribus mos re voluptis porehentias doloremposam ut pa ped quatibusda verspidia qui ullabo. Tate nim nonsece atistium lab ipsamen ditate porem arum rem remperro volorectota verias ad ulluptatem simoluptum quae recaece pudam, sin rem nis quam voluptas simet ut quam,
HOME ABOUT SERVICES CONTACT
LOG IN Username
Password
LOG IN
TUMOR COMPASS
Lung Cancer
xxx
DOWNLOAD VIDEO AUDIO
Ribus mos re voluptis porehentias doloremposam ut pa ped quatibusda verspidia qui ullabo. Tate nim nonsece atistium lab ipsamen ditate porem arum rem remperro volorectota verias ad ulluptatem simoluptum quae recaece pudam, sin rem nis quam voluptas simet ut quam,
TUMOR COMPASS
Lung Cancer
xxx
DOWNLOAD VIDEO AUDIO
Ribus mos re voluptis porehentias doloremposam ut pa ped quatibusda verspidia qui ullabo. Tate nim nonsece atistium lab ipsamen ditate porem arum rem remperro volorectota verias ad ulluptatem simoluptum quae recaece pudam, sin rem nis quam voluptas simet ut quam,
TUMOR COMPASS
Lung Cancer
Rum latiandest pratempos quia sinullorum, qui arciatus sin nonsequodi as pro occuptae paruptate magnam vo-luptaqui debitas aliqui sequiscipici omnimodis si tet repere presequiamus sitam, cum andi ut magnis explite rerferu ptium, omnimus pore volorup taspero videbissint ut illandae seque duntinctiant porem ex ea aut qui dolupie ndisto que ipsaeped quam, sita con et denim que pro offictint.As aut ium nam ex essita doluptae nonsequos et pa sam eate consed unt quuntesed ma perum sed esciis re pere si id molumquis etus, sam quias cus essimpe ruptaeri dolupid quiatquibus, aut ut aut pla corepudanis ratur magnament utem enimolorundi accusciatius por sum quos dolor sequi solore vitem accus dolles accuptas moluptia cumquae omni rae ommolor aut venihitatem atur, odi dolliant aut que rectiunt este perions equiae. Pa poratus dandaes dolorib uscit, es dolor same niatur, soloreiumquo ipsus cusantium dolorum nis impereptat restis consenimpor sumIqui ario consequid qui blaborporia doluptatum et quaepe provit, omnihiciur aut eumque sam que omnihit iosanditate nobit
TABLE OF CONTENTS
DOWNLOADS
Chapter 1
Chapter 2
Chapter 3
Chapter 4
Chapter 5
John Eckardt, MDEbis adit fuga. Utaspitat.Oditat. Repta dero moluptae. Nament pel invelique aut utentias doluptat qua-tatur re sime nihilla cessitat ut eniantio
BREAST COMPASS- John Eckardt, MD
LUNG COMPASS- John Eckardt, MD
CLL COMPASS- John Eckardt, MD
Audio
Video
Transcript
[advertising] educational tool. 2012.
“In multivariate analysis, luminal/HER2 and HER2-enriched tumors were associated with a significantly higher rate of brain, liver, and lung metastases.”
- Kennecke et al., J Clin Oncol. 2010
“HER2 overexpression was predictive of CNS involvement by multivariate analysis.”
- Miller et al., Ann Oncol. 2003
HER2 amplification correlates with
increased risk of metastasis 02
HER2+HER2 amplification correlates with increased risk of metastasisEvery HER2+ visceral patient is high-risk, regardless of HR status
Subthemes References
Supportive referenceHER2+ mBC patients develop CNS metastases more readily than HER2- patients
Miller et al., Ann Oncol. 2003Gabos et al., J Clin Oncol. 2006
Additional referencesPreclinical
HER2-overexpressing NCI-H460 cells exhibit increased metastatic potential in vivo and in vitro Yu et al., Cancer Res. 1994
MetastaticCorrelation between lymph node metastases and HER2 overexpression in node-positive breast cancer patients
Slamon et al., Science. 1987Slamon et al., Science. 1989
Greater risk of CNS metastasis associated with HER2+ status than with other prognostic factors Pestalozzi et al., Ann Oncol. 2006
Metastases at multiple sites are more common in HER2-enriched breast cancer patients
Kennecke et al., J Clin Oncol. 2010
ReviewPositive HER2 status is predictive of increased CNS metastasis risk Nguyen et al., Neurol Clin. 2007
Nahta et al., Cancer Res. 2004
HER2+To target HER2, trastuzumab alone is now suboptimal
Dual blockade more efficiently inhibits breast cancer growth in trastuzumab-resistant cells
> Back to reference page
Impact and Statements• The current preclinical study determined
the ability of combined anti-HER2 therapy to inhibit breast cancer cell proliferation and survival in HER2-overexpressing BT474 cells
• Dual blockade more efficiently inhibited breast cancer growth than either agent independently
Anti-HER2 Combination Inhibits Breast Cancer Growth• BT474 cells were treated with trastuzumab
and/or the HER2/HER3 dimer inhibitor at a fixed 1:1 ng/ml drug concentration ratio; dual blockade mediated a loss of up to 60% of cells at doses in which cells were resistant to trastuzumab or the HER2/HER3 dimer inhibitor alone
Anti-HER2 Combination Induces Apoptosis• Cell cycle analysis was performed to
determine whether the results of the dose-response assays were due to cell cycle arrest or apoptosis
• Dual blockade increased the subdiploid fraction; in addition, the anti-HER2 combination reduced the percentage of proliferating (S-phase) cells
RN=469
Chemotherapy- HER2+ metastatic breast cancer- No prior chemotherapy for metastatic disease
Chemotherapy +trastuzumab
12 wks
24 wks
36 wks
48 wks
-5
5
15
Mea
n C
hang
e in
Sco
re
-15
0
NR R
Global QOL
NR R
Physical
NR R
Social
NR R
Role
NR R
Fatigue
10
-10
HER2+metastatic breast cancercreated by ONE Oncology
[advertising] rotating web banner. 2013.
[advertising] web banner samples. 2013.
PREVENTION & DIAGNOSTIC E V A L U A T I O N
O F N S C LC
A DVA N C E DM E T A S T A T I C
EVOLUTION OF CARE-LOCALLY
L U N G C A N C E R
&
A D V A N C E S I N T H E R A P Y F O R
E G F R mut & A L K R E A R R A N G E D
L U N GC A N C E R
I N N S C L C
E V O L V I N G R O L E O F
VEGF & MET